← Eichor
Study identifier: NCT06079294 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism

Condition: Autoimmune Encephalitis  ·  Sponsor: Assistance Publique - Hôpitaux de Paris

PhaseNA
Planned participants56
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Prospective cohort study evaluating FDG PET in 56 patients with confirmed autoimmune encephalitis - based on 2016 Graus criteria, and 2021 paraneoplastic neurological syndromes criteria - at the acute phase, before immunomodulating treatment, or within 10 days of treatment initiation.

This description comes directly from the study's public registry record.

Talk to the study team

Aurélie Kas, Pr  ·  01 42 17 62 81  ·  aurelie.kas@aphp.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hospital Pitie SalpetriereParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06079294